Editas Medicine, Inc. (EDIT) and Allegan plc (AGN) announced they have dosed the first patient in a Phase I/II study called BRILLIANCE to evaluate their CRISPR-based candidate, AGN-151587 (EDIT-101), in patients with Leber congenital amaurosis 10 (LCA10), an inherited...